Tratamiento con hormona de crecimiento y craneofaringioma: presentación de caso
Files
View full text
View full text
View full text
View full text
View full text
View full text
View full text
View full text
View full text
View full text
View full text
View full text
View full text
View full text
View full text
View full text
View full text
View full text
View full text
View full text
View full text
View full text
View full text
View full text
View full text
View full text
View full text
View full text
View full text
View full text
View full text
View full text
View full text
View full text
View full text
View full text
View full text
View full text
View full text
View full text
View full text
View full text
View full text
View full text
View full text
View full text
View full text
View full text
View full text
View full text
View full text
View full text
View full text
View full text
View full text
Date
Authors
Subject
craniopharyngioma
growth hormone
hypopituitarism
craneofaringioma
hormona de crecimiento
hipopituitarismo
growth hormone
hypopituitarism
craneofaringioma
hormona de crecimiento
hipopituitarismo
Language:
Journal Title
Journal ISSN
Volume Title
Publisher
Intituto Tecnológico de Santo Domingo (INTEC)
El craneofaringioma es el tumor más frecuente de la edad pediátrica. Se localiza frecuentemente en el área supraselar; histológicamente benigno, pero con carácter expansivo que provoca manifestaciones clínicas secundarias a la afectación de estructuras vecinas. El tratamiento es quirúrgico y, en la mayoría de los casos, trae como consecuencia un panhipopituitarismo. El tratamiento con hormona de crecimiento (GH) en estos casos es un tema de debate. A nivel internacional se ha realizado en situaciones excepcionales, obteniendo resultados favorables. En Cuba, este es el primer caso dentro de una casuística de 813 pacientes tratados con GH, en 12 años de experiencia.Describimos el caso clínico de una paciente con diagnóstico de craneofaringioma, operada, que recibió tratamiento con hormona de crecimiento. Se trata de una fémina que a los 9 años de edad inicia sus estudios por presentar talla baja. Se le realizó test de clonidina que reveló déficit de GH. En la tomografía computarizada de cráneo se observó lesión hipofisaria de 2 cm de diámetro que ocupa cisterna supraselar, con lo que se llega al diagnóstico de un craneofaringioma. Se lleva a cabo la intervención quirúrgica con resección total macroscópica del tumor. Posteriormente, se instaura un panhipopituitarismo, por lo que se realiza sustitución del eje tiroideo, adrenal, gonadal y hormona antidiurética. Se evalúa alteración del crecimiento, ausencia de recidiva tumoral y, con el consentimiento de la familia, se inicia tratamiento con GH, con lo que se obtiene ganancia de talla favorable de 39 cm/5años, sin evidencia de recidiva tumoral.
Craniopharyngioma is the most frequent tumor of the pediatric age. It is frequently located in the suprasellar area; histologically benign, but with expansive character that causes clinical manifestations secondary to the involvement of neighboring structures. The treatment is surgical and, in most cases, results in panhypopituitarism. The treatment with growth hormone (GH) in these cases is a subject of debate. At an international level, it has been carried out in exceptional situations, obtaining favorable results. In Cuba, this is the first case in a casuistry of 813 patients treated with GH, in 12 years of experience.We describe the clinical case of a patient with a diagnosis of operated craniopharyngioma who received treatment with growth hormone. This is a female who, at 9 years of age, starts her studies because she has short stature. A clonidine test was performed, which revealed GH deficiency. In the cranial computed tomography, a pituitary lesion 2 cm in diameter was observed that occupies a suprasellar cistern, which leads to the diagnosis of a craniopharyngioma. Surgical intervention is carried out with macroscopic total resection of the tumor. Subsequently, a panhypopituitarism is established, which is why the thyroid, adrenal, gonadal and antidiuretic hormone are replaced. Growth alteration, absence of tumor recurrence is evaluated and, with the consent of the family, treatment with GH is initiated, obtaining a favorable height gain of 39 cm / 5 years, without evidence of tumor recurrence.
Craniopharyngioma is the most frequent tumor of the pediatric age. It is frequently located in the suprasellar area; histologically benign, but with expansive character that causes clinical manifestations secondary to the involvement of neighboring structures. The treatment is surgical and, in most cases, results in panhypopituitarism. The treatment with growth hormone (GH) in these cases is a subject of debate. At an international level, it has been carried out in exceptional situations, obtaining favorable results. In Cuba, this is the first case in a casuistry of 813 patients treated with GH, in 12 years of experience.We describe the clinical case of a patient with a diagnosis of operated craniopharyngioma who received treatment with growth hormone. This is a female who, at 9 years of age, starts her studies because she has short stature. A clonidine test was performed, which revealed GH deficiency. In the cranial computed tomography, a pituitary lesion 2 cm in diameter was observed that occupies a suprasellar cistern, which leads to the diagnosis of a craniopharyngioma. Surgical intervention is carried out with macroscopic total resection of the tumor. Subsequently, a panhypopituitarism is established, which is why the thyroid, adrenal, gonadal and antidiuretic hormone are replaced. Growth alteration, absence of tumor recurrence is evaluated and, with the consent of the family, treatment with GH is initiated, obtaining a favorable height gain of 39 cm / 5 years, without evidence of tumor recurrence.
Description
Type
info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
info:eu-repo/semantics/publishedVersion
Source
Science and Health; Vol 2 No 1 (2018): Science and Health, january-april; 15-20
Ciencia y Salud; Vol. 2 Núm. 1 (2018): Ciencia y Salud, enero-abril; 15-20
2613-8824
2613-8816
10.22206/cysa.2018.v2i1
Ciencia y Salud; Vol. 2 Núm. 1 (2018): Ciencia y Salud, enero-abril; 15-20
2613-8824
2613-8816
10.22206/cysa.2018.v2i1